BioAge Stock Rallies 29% Following Upsized $198M IPO
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
Sector Update: Health Care
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Tech Stocks Lead Rally
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia
Novo Nordisk Senate Hearing Removes a Share Overhang -- Market Talk
Evotec, Novo Nordisk Forms Technology Development Partnership for Stem Cell-based Therapies
Oppenheimer points out the next "trend" for weight loss drugs: oral over-the-counter medication.
The competition to develop oral weight-loss drugs is intensifying.
Lose Weight With Novo Nordisk Drugs, Gain Money With Stock
Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users
Next Frontier in Anti-obesity Landscape: Oral GLP-1s With Potential OTC Switch
Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
BioAge, Obesity Drug Developer, Upsizes Proposed IPO
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
Novo Nordisk, Lilly Weight Loss Drugs Poised for Price Reductions: Cantor's Louise Chen
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160
Critics complained that the pricing was too high! novo-nordisk a/s exclaimed, "Unjustly accused" because third parties took kickbacks.
The giant rises rapidly.
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
U.S. Senate questions high pricing of 'miracle weight-loss drug' novo-nordisk a/s responds: lowering the price is useless.
①Novo Nordisk's CEO was questioned by the United States Senate, with senators believing that Novo Nordisk's pricing in the USA is too high; ②At the hearing, Novo Nordisk's CEO still refused to commit to lowering the prices of Wegovy and Ozempic; ③After the hearing, Novo Nordisk issued a statement saying that even if the company lowers prices, American patients would not be able to enjoy the corresponding price reductions.